Proceedings of the AGM of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals held its 33rd AGM on September 27, 2025 via video conferencing, with 62 public shareholders present (out of 77,961 total shareholders), while no promoter shareholders attended. Shareholders approved 14 resolutions covering routine items (adoption of FY25 financial statements, re-appointment of director Mr. Ravi Thakor, appointment of statutory and secretarial auditors) and several major corporate actions. Key special resolutions approved include a stock split/sub-division of equity shares, a bonus issue, an increase in authorised share capital, a Qualified Institutions Placement (QIP) of up to Rs. 80 crores, raising the FPI/FII holding limit to 49%, and increasing the Section 186 loans/investments threshold. The statutory auditor gave a Disclaimer of Opinion (qualification), though management stated it does not affect company functioning. Three directors (Mr. Ravi Thakor, Mr. Yogeshkumar Prajapati, and Mrs. Bhumika Pradhan) were regularized in their positions.
The AGM cleared the path for significant capital actions — a stock split, a bonus issue, an authorised capital hike, and an Rs. 80-crore QIP — which could dilute existing shareholders but also bring in fresh funds. The auditor's Disclaimer of Opinion is a red flag on financial reporting quality, and the absence of promoters at the AGM may raise corporate governance concerns among retail investors.